Water Tower Research Highlights Ainos' SmellTech Platform AI Nose as Foundational AI Innovation
Ainos (NASDAQ:AIMD) received recognition from Water Tower Research for its AI Nose platform, an advanced smell digitization technology. The platform demonstrates impressive accuracy rates: 90+% in distinguishing everyday scents, 85% in senior care environments, and 80% across 22 industrial scent types in semiconductor settings.
Built on over a decade of innovation, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays. The technology utilizes a smell language model (SLM) that improves with continuous use, creating a data-driven flywheel effect. The company is pursuing strategic partnerships, particularly in Asia, to accelerate commercialization across healthcare, industrial, and robotics markets.
Ainos (NASDAQ:AIMD) ha ricevuto un riconoscimento da Water Tower Research per la sua piattaforma AI Nose, una tecnologia avanzata di digitalizzazione degli odori. La piattaforma mostra tassi di accuratezza impressionanti: oltre il 90% nel distinguere gli odori quotidiani, il 85% negli ambienti di assistenza agli anziani e l'80% in 22 tipi di odori industriali nel settore dei semiconduttori.
Basata su oltre un decennio di innovazione, AI Nose combina calibrazione avanzata, elaborazione del segnale ad alta precisione e array di sensori personalizzati. La tecnologia utilizza un modello linguistico degli odori (SLM) che migliora con l'uso continuo, creando un effetto volano basato sui dati. L'azienda sta cercando partnership strategiche, soprattutto in Asia, per accelerare la commercializzazione nei mercati della sanità, dell'industria e della robotica.
Ainos (NASDAQ:AIMD) recibió reconocimiento de Water Tower Research por su plataforma AI Nose, una tecnología avanzada de digitalización de olores. La plataforma demuestra tasas impresionantes de precisión: más del 90% para distinguir olores cotidianos, 85% en entornos de cuidado de personas mayores y 80% en 22 tipos de olores industriales en entornos de semiconductores.
Construida sobre más de una década de innovación, AI Nose combina calibración avanzada, procesamiento de señales de alta precisión y matrices de sensores personalizadas. La tecnología utiliza un modelo de lenguaje olfativo (SLM) que mejora con el uso continuo, creando un efecto de impulso basado en datos. La empresa busca alianzas estratégicas, especialmente en Asia, para acelerar la comercialización en los mercados de salud, industria y robótica.
Ainos (NASDAQ:AIMD)는 첨단 냄새 디지털화 기술인 AI Nose 플랫폼으로 Water Tower Research의 인정을 받았습니다. 이 플랫폼은 일상적인 냄새 구분에서 90% 이상의 정확도, 노인 돌봄 환경에서 85%, 반도체 산업 환경의 22가지 산업용 냄새 유형에서 80%의 우수한 정확도를 보여줍니다.
10년 이상의 혁신을 바탕으로 AI Nose는 고급 보정, 고정밀 신호 처리 및 맞춤형 센서 배열을 결합합니다. 이 기술은 지속적인 사용으로 향상되는 냄새 언어 모델(SLM)을 활용하여 데이터 기반의 선순환 효과를 창출합니다. 회사는 특히 아시아에서 전략적 파트너십을 추진하여 의료, 산업, 로봇 시장 전반에 걸친 상용화를 가속화하고자 합니다.
Ainos (NASDAQ:AIMD) a été reconnu par Water Tower Research pour sa plateforme AI Nose, une technologie avancée de numérisation des odeurs. La plateforme affiche des taux de précision impressionnants : plus de 90% pour distinguer les odeurs quotidiennes, 85% dans les environnements de soins aux personnes âgées, et 80% pour 22 types d’odeurs industrielles dans le secteur des semi-conducteurs.
Fondée sur plus d’une décennie d’innovation, AI Nose combine une calibration avancée, un traitement du signal haute précision et des réseaux de capteurs personnalisés. La technologie utilise un modèle linguistique des odeurs (SLM) qui s’améliore avec l’usage continu, créant un effet de boucle vertueuse basé sur les données. L’entreprise cherche à établir des partenariats stratégiques, notamment en Asie, afin d’accélérer la commercialisation dans les secteurs de la santé, de l’industrie et de la robotique.
Ainos (NASDAQ:AIMD) erhielt von Water Tower Research Anerkennung für seine AI Nose Plattform, eine fortschrittliche Technologie zur Digitalisierung von Gerüchen. Die Plattform zeigt beeindruckende Genauigkeitsraten: über 90% bei der Unterscheidung alltäglicher Düfte, 85% in der Seniorenbetreuung und 80% bei 22 industriellen Duftarten im Halbleiterbereich.
Basierend auf über einem Jahrzehnt Innovation kombiniert AI Nose fortschrittliche Kalibrierung, hochpräzise Signalverarbeitung und maßgeschneiderte Sensorsysteme. Die Technologie nutzt ein Geruchssprachmodell (SLM), das sich mit fortlaufender Nutzung verbessert und so einen datengetriebenen Schwungradeffekt erzeugt. Das Unternehmen strebt strategische Partnerschaften an, insbesondere in Asien, um die Kommerzialisierung in den Bereichen Gesundheitswesen, Industrie und Robotik zu beschleunigen.
- None.
- Early stage of commercialization with partnerships still being developed
- Heavy reliance on Asian market for initial commercial deployment
Insights
Ainos' AI Nose platform shows impressive accuracy metrics across multiple sectors while building a valuable proprietary scent dataset moat.
Ainos is positioning itself at the frontier of an underexplored AI sensory domain - digital olfaction. While vision and voice AI have seen tremendous advancement, smell digitization remains relatively untapped despite its significant potential across multiple industries. The company's AI Nose platform demonstrates 90+% accuracy for everyday scents, 85% in senior care, and 80% across 22 industrial semiconductor scents - metrics that validate its technical capabilities.
What's particularly valuable is the platform's improving smell language model (SLM) that creates a data flywheel effect. Each new scent interaction strengthens their proprietary dataset, enhancing the technology while simultaneously widening their competitive moat. This data accumulation strategy mirrors the approach that has powered leaders in other AI domains.
The technology's versatility across healthcare, industrial applications, and robotics indicates multiple revenue pathways rather than dependence on a single vertical. Their strategic focus on Asian markets leverages regional strengths in electronics manufacturing, semiconductors, and robotics - sensible for initial commercialization while they explore US and European partnerships.
The decade of technical development behind AI Nose suggests significant R&D investment and intellectual property accumulation, creating barriers to entry for potential competitors. This established foundation in an emerging sensory AI category positions Ainos favorably as olfactory AI applications expand across industries.
AI Nose delivers accuracy and versatility, driving scalable growth across healthcare, industrial and robotics markets
Technology, data moat, and strategic partnerships position Ainos for accelerated commercial readiness and expansion
SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research has published a recap of its recent Small-Cap Spotlight podcast. The report highlights the Company's AI Nose platform, an advanced smell digitization technology powered by artificial intelligence and built on over a decade of innovation, a deep data moat, strategic partnerships, and a clear commercialization roadmap. The report identifies AI Nose as a foundational innovation in olfactory AI, a rapidly emerging and underdeveloped frontier within the sensory AI landscape.
Key Highlights from the Report:
AI Nose establishes olfactory AI as a powerful new tool for industrial intelligence, combining accuracy with adaptability: AI Nose delivers 90+% accuracy in distinguishing everyday scents,
85% in senior care environments, and80% across 22 industrial scent types in semiconductor settings. Its AI model, smell language model (SLM), improves with each use, creating a powerful data-driven flywheel effect that can support scalable deployment across multiple high-growth verticals.Early-mover innovation and data moat cement AI Nose's distinct competitive edge in smell digitization: While most AI innovation has focused on vision and voice, Ainos positions smell as a high-impact, underdeveloped frontier. Built on over a decade of technical innovation and a growing scent dataset, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays into a powerful scent sensing platform. Originally developed for medical use, the platform has expanded into robotics, semiconductor manufacturing, and industrial automation, positioning it as a frontrunner in the fast-emerging field of olfactory AI.
Strategic partnerships fuel commercial scale-up across key verticals: Ainos is rapidly expanding AI Nose's market reach and accelerating commercialization through strategic alliances - with more likely to come. The Company sees Asia as a key launchpad given the region's strengths in electronic manufacturing services, semiconductors, automation and robotics. At the same time, Ainos welcomes partnership opportunities in the U.S. and Europe to support global commercialization.
Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_07202025
Those interested can listen to the full podcast via Apple Podcasts, Spotify, or Water Tower Research's website.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What accuracy rates does Ainos (NASDAQ:AIMD) AI Nose technology achieve?
What markets is Ainos targeting with its AI Nose platform?
How does Ainos AI Nose technology improve over time?
What competitive advantages does Ainos (AIMD) have in smell digitization?
What is Ainos commercialization strategy for AI Nose?
